← Companies|Eliem Therapeutics
El

Eliem Therapeutics

Redmond WAFounded 201930 employees
Private CapbiotechAcquiredCNS
Platform: Pain Channel
Market Cap
N/A
All Drugs
3
Clinical Trials
3
Failed / Terminated
1
FDA Approved
0
Drug Pipeline (3 programs)
Drug NameCodePhaseTrialsModalityTargetMOAIndications
DatorasimodELI-8500NDA/BLA1VaccineFGFRALKiT2DPancreatic Ca
TalalucimabELI-3128Preclinical1mAbB7-H3BTKiSCLC
ELI-3182ELI-3182Preclinical1siRNAPLK4PI3KiIPFAS
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (3)
2025-06-24
Talalucimab Interim
SCLC
Past
2025-06-26
ELI-3182 Interim
IPF
Past
2026-10-11
Datorasimod Ph3 Readout
NB
Ph3 Readout